Predicting Colorectal Cancer Occurrence in IBD

Abstract

Patients with colonic inflammatory bowel disease (IBD) are at an increased risk of developing colorectal cancer (CRC), and are therefore enrolled into a surveillance programme aimed at detecting dysplasia or early cancer. Current surveillance programmes are guided by clinical, endoscopic or histological predictors of colitis-associated CRC (CA-CRC). We have seen great progress in our understanding of these predictors of disease progression, and advances in endoscopic technique and management, along with improved medical care, has been mirrored by the falling incidence of CA-CRC over the last 50 years. However, more could be done to improve our molecular understanding of CA-CRC progression and enable better risk stratification for patients with IBD. This review summarises the known risk factors associated with CA-CRC and explores the molecular landscape that has the potential to complement and optimise the existing IBD surveillance programme.

Keywords: cancer risk; inflammatory bowel disease; molecular biomarkers; molecular risk factors; risk factors.

Figure 1

Demonstrates the known risk factors for predicting cancer risk in patients with IBD, and illustrates the potential novel directions for a molecular biomarker for disease progression. CIB—cumulative inflammatory burden, CRP—C-reactive protein.